Hong Kong-listed Zhaoke Ophthalmology Limited completed on-market buybacks of 1.56 million ordinary shares between 11 and 26 June 2026, according to its latest Next Day Disclosure Return filed on 26 June 2026.

• Scale of repurchase – Aggregate shares bought: 1,561,000, equivalent to 2.61% of the 54.87 million shares authorised for buy-back under the mandate approved on 15 May 2026. – Relative to the 548.75 million issued shares outstanding, the repurchased amount represents about 0.28%. – All repurchased shares are earmarked for cancellation; none will be held as treasury stock.

• Pricing details – Transaction dates: 11, 15, 16, 22, 23, 24, 25 and 26 June 2026. – Volume-weighted average repurchase prices ranged from HKD 2.44 to HKD 2.83 per share. – The latest buy-back on 26 June involved 126,500 shares at HKD 2.44 per share, costing HKD 0.31 million.

• Capital structure unchanged for now – Despite the buy-backs, total issued shares remain at 548.75 million as of 26 June 2026 because the repurchased shares had not yet been cancelled. – No treasury shares are currently held.

• Mandate headroom and issuance restriction – After the recent transactions, 53.31 million shares, or about 97.4% of the authorised limit, remain available under the existing repurchase mandate. – In accordance with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares, expiring on 26 July 2026.

All repurchases were executed on the Hong Kong Stock Exchange and, according to the company, complied with the Main Board Listing Rules and the terms of its April 2026 explanatory statement.